Hsbc Holdings PLC Sells 65,993 Shares of Moderna, Inc. $MRNA

Key Points

• HSBC Holdings PLC reduced its stake in Moderna, Inc. by 9.4%, owning 632,671 shares valued at approximately $17.9 million after selling 65,993 shares in the first quarter.
• Moderna reported a quarterly loss of ($2.13) earnings per share, which exceeded analyst expectations, but its revenue fell 41.1% year-over-year to $142 million.
• Analysts have a consensus "Hold" rating for Moderna stock, with a price target averaging $42.88, despite a recent target cut from some firms, including Barclays and Bank of America.

Hsbc Holdings PLC lowered its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 9.4% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 632,671 shares of the company's stock after selling 65,993 shares during the period. Hsbc Holdings PLC owned 0.16% of Moderna worth $17,913,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of MRNA. Voloridge Investment Management LLC increased its holdings in shares of Moderna by 335.6% in the fourth quarter. Voloridge Investment Management LLC now owns 2,590,831 shares of the company's stock valued at $107,727,000 after purchasing an additional 1,996,003 shares in the last quarter. Invesco Ltd. increased its holdings in shares of Moderna by 17.5% in the first quarter. Invesco Ltd. now owns 5,883,624 shares of the company's stock valued at $166,801,000 after purchasing an additional 877,162 shares in the last quarter. Nuveen LLC acquired a new stake in shares of Moderna in the first quarter valued at approximately $19,510,000. Deutsche Bank AG increased its holdings in shares of Moderna by 54.7% in the fourth quarter. Deutsche Bank AG now owns 1,894,075 shares of the company's stock valued at $78,756,000 after purchasing an additional 669,614 shares in the last quarter. Finally, TB Alternative Assets Ltd. acquired a new stake in shares of Moderna in the first quarter valued at approximately $18,495,000. Institutional investors and hedge funds own 75.33% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on MRNA shares. Wells Fargo & Company reaffirmed an "equal weight" rating on shares of Moderna in a report on Sunday, July 13th. Cowen started coverage on shares of Moderna in a report on Sunday, July 13th. They set a "hold" rating for the company. Barclays lowered their target price on shares of Moderna from $40.00 to $31.00 and set an "equal weight" rating for the company in a report on Monday, August 4th. Bank of America lowered their target price on shares of Moderna from $26.00 to $25.00 and set an "underperform" rating for the company in a report on Tuesday, July 22nd. Finally, JPMorgan Chase & Co. set a $26.00 target price on shares of Moderna in a report on Friday, August 1st. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, sixteen have issued a Hold rating and four have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Moderna currently has a consensus rating of "Hold" and a consensus target price of $42.88.

Moderna Price Performance

Shares of NASDAQ MRNA traded down $0.59 during midday trading on Friday, reaching $23.88. 3,104,792 shares of the stock were exchanged, compared to its average volume of 10,698,186. The business has a 50-day simple moving average of $29.12 and a two-hundred day simple moving average of $28.89. The company has a market capitalization of $9.29 billion, a price-to-earnings ratio of -3.17 and a beta of 1.83. Moderna, Inc. has a 12 month low of $23.15 and a 12 month high of $79.96.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings results on Friday, August 1st. The company reported ($2.13) earnings per share for the quarter, topping analysts' consensus estimates of ($2.99) by $0.86. The company had revenue of $142.00 million for the quarter, compared to analysts' expectations of $116.26 million. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The business's quarterly revenue was down 41.1% compared to the same quarter last year. During the same period last year, the firm posted ($3.33) earnings per share. Moderna has set its FY 2025 guidance at EPS. Equities research analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.